Developing new antibiotics to fight drug-resistant infections
Official title: A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens
Funded at Curza INC · NIH-10892244 · Data updated 2026-11-12
This study is testing a new antibiotic called CZ-02 that aims to help people with tough infections, like urinary tract infections, caused by bacteria that are hard to treat because they resist current antibiotics.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Curza INC NIH-funded |
| Lab location | 1 site (Salt Lake City, UNITED STATES) |
| Project start | July 21, 2023 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,000,000 |
| NIH project number | 5R44AI170297-02 |
| Project ID | NIH-10892244 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients suffering from infections caused by multidrug-resistant bacteria, particularly those with urinary tract infections.
✕Less likely to help
Patients with infections caused by bacteria that are not multidrug-resistant may not receive benefit from this research.
What this research studies
This research focuses on creating a new class of broad-spectrum antibiotics called CZ-02, which targets multidrug-resistant Gram-negative bacteria, including Acinetobacter baumannii. The approach involves binding to a unique site on the bacterial ribosome, which helps prevent the development of resistance to existing antibiotics. The project aims to develop a drug candidate that is effective against both Gram-negative and Gram-positive pathogens, with initial applications for treating urinary tract infections. Patients may benefit from a more effective treatment option for infections that are currently difficult to manage due to antibiotic resistance.
Why it matters
Potential benefit: If successful, this research could provide patients with new treatment options for infections caused by multidrug-resistant bacteria.
How similar studies have gone: Other research has shown promise in developing new antibiotics targeting resistant bacteria, but this specific approach is relatively novel.
Where this research is happening
-
Curza INC
Salt Lake City, United States Active
Researchers
- Principal investigator: Sebahar, Paul — Curza INC
- Study coordinator: Sebahar, Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.